Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1903 1
1936 1
1947 1
1987 1
1988 1
1990 3
1991 1
1992 5
1993 11
1994 3
1995 1
1996 4
1997 7
1998 4
1999 5
2000 8
2001 5
2002 6
2003 3
2006 4
2007 6
2008 2
2009 3
2010 4
2011 2
2012 7
2013 5
2014 6
2015 3
2016 1
2017 5
2018 3
2019 4
2020 5
2021 7
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12736113

132 results

Results by year

Filters applied: . Clear all
Page 1
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A; Austrian Ovarian Cancer Study Group. Dittrich Ch, et al. Eur J Cancer. 2003 May;39(8):1129-40. doi: 10.1016/s0959-8049(03)00152-7. Eur J Cancer. 2003. PMID: 12736113 Clinical Trial.
High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F, Héron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhommé C, Macé-Lesec'h J, Crouet H. Joly F, et al. Gynecol Oncol. 2000 Sep;78(3 Pt 1):361-8. doi: 10.1006/gyno.2000.5923. Gynecol Oncol. 2000. PMID: 10985895 Clinical Trial.
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC. van der Burg ME, et al. Eur J Cancer. 2014 Oct;50(15):2592-601. doi: 10.1016/j.ejca.2014.07.015. Epub 2014 Aug 2. Eur J Cancer. 2014. PMID: 25096168 Clinical Trial.
A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. Högberg T, et al. Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420. Acta Oncol. 2001. PMID: 11441940 Review.
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. Rosell R, et al. Ann Oncol. 2002 Oct;13(10):1539-49. doi: 10.1093/annonc/mdf332. Ann Oncol. 2002. PMID: 12377641 Free article. Clinical Trial.
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ. Alberts DS, et al. J Clin Oncol. 1992 May;10(5):706-17. doi: 10.1200/JCO.1992.10.5.706. J Clin Oncol. 1992. PMID: 1569443 Clinical Trial.
132 results